Elnaz Atabakhsh, PhD
Elnaz Atabakhsh, Ph.D. is the Executive Director of C-Path’s Type 1 Diabetes Consortium (T1DC). Throughout her career, Elnaz has been deeply motivated by, and committed to the development of therapeutic and diagnostic tools, particularly in indications with significant unmet patient need.
Prior to joining C-Path, Elnaz was the Associate Director of Scientific Collaborations and Alliances at Repertoire Immune Medicines where she led academic and industry collaborations in support of Repertoire’s autoimmune and oncology discovery programs, and Senior Program Manager at Agios Pharmaceuticals where she supported early-stage discovery programs in genetically-defined diseases and oncology. Prior to these roles, Elnaz spent five years at Abcam Inc. where she was the strategic lead for Abcam’s biomarker profiling platform. In this role, Elnaz oversaw the development and launch of high-throughput genomic and proteomic biomarker assays, and established numerous long-term collaborations with partners in industry, academia, and nonprofit organizations aimed at advancing biomarker discovery and screening in drug-induced organ injury, oncology, and neurodegenerative diseases.
Elnaz received her B.Sc. and Ph.D. degrees in Biochemistry from the University of Ottawa and the University of Western Ontario respectively, after which she completed a postdoctoral fellowship in cancer epigenetics at the Massachusetts General Hospital Cancer Center and Harvard Medical School. Elnaz is excited to apply her passion for patient-oriented, mission-driven work to advancing the goals of the Type 1 Diabetes Consortium at C-Path.